R 2 is selected from the group consisting of: hydrogen, ~ HPO(OY) 2 , " * ~ PO(OH) 2 , and - C(=0)-Y, where Y is -Z-(CH2)q-W-R b , q is 0-4, where Z and W are independently selected from the group consisting of: CH2, O, S, R C and R b , where R c is selected from the group consisting of: hydrogen, C1-C4 alkyl, and C3-C6 cycloalkyl, R b is selected from the group consisting of: hydrogen, C1-C12 alkyl, C1-C12 substituted alkyl, C3-C8 cycloalkyl, C3-C8 substituted cycloalkyl, C3-C8 heterocycloalkyl, and C3-C8 substituted heterocycloalkyl, or alternatively -C(=0)-Y forms an amide bond thru a nitrogen atom on Y in which case Y is a selected from the group consisting of: glycine, sarcosine, ,-diemthyl glycine, alanine, valine, leucine, isoleucine, lysine, ornithine, arigine, serine, and theronine
& Scadden, D
Route-Dependent Bioavailability: Subcutaneous, intraperitoneal, or intravenous administration affects pharmacokinetics Experimental Design Recommendations: Control Groups: Vehicle control (vehicle buffer, volume-matched) Cagrilintide alone (matched to blend concentration) Semaglutide alone (matched to blend concentration) Blend combination (test group) Positive control (reference compound: e.g., native amylin, native GLP-1, alternative agonists such as Mazdutide) Negative control (receptor antagonists if available) Pharmacokinetic and Pharmacodynamic Considerations: Extended Half-Lives: Both peptides feature ~7-day half-lives enabling once-weekly administration in animal models Steady-State: Account for 3-5 half-lives to reach steady-state (~3-5 weeks) Accumulation: Consider accumulation with repeated administration
If necessary, opt for goat milk instead of cow milk
